January 27, 2021
Business News

AVROBIO Announces Proposed Public Offering of Common Stock


CAMBRIDGE, Mass.–()–AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.

The company expects to grant the underwriters a 30-day option to purchase up to $11.25 million of additional shares of its common stock (15 percent) offered in the public offering. All of the shares in the proposed offering are to be sold by the company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Morgan Stanley,…



Click here to view the original article.

Related Posts

You might also like ...

Pelican Products Promotes Kevin Murphy to Lead Marketing for the U.S.
AON Splash Image
Booksy raises $70 million to bring its beauty and wellness appointment booking app to even more salons and customers across the US, UK, and EU
Essential Declares March 2021 Dividend